Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD

Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty‐two asthmat...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental allergy Vol. 43; no. 7; pp. 730 - 740
Main Authors Choi, G.-S., Kim, J.-H., Shin, Y.-S., Ye, Y.-M., Kim, S.-H., Park, H.-S.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.07.2013
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0954-7894
1365-2222
1365-2222
DOI10.1111/cea.12096

Cover

Abstract Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty‐two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine‐aspirin nasal provocation test (L‐ASA NPT) and 14 aspirin‐tolerant asthma (ATA) patients who showed negative responses to the L‐ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L‐ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L‐ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Results Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up‐regulation of apolipoprotein A1 (ApoA1), α2‐macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients. Conclusion Eosinophil activation occurred in early and late responses after L‐ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.
AbstractList Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Results Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), [alpha]2-macroglobulin ([alpha]2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, [alpha]2M and CP levels during the early response in AERD patients. Conclusion Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, [alpha]2M and CP as well as CysLT may be involved in eosinophilic inflammation. [PUBLICATION ABSTRACT]
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), alpha 2-macroglobulin ( alpha 2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, alpha 2M and CP levels during the early response in AERD patients. Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, alpha 2M and CP as well as CysLT may be involved in eosinophilic inflammation.
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).BACKGROUNDEosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics.OBJECTIVETo investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics.Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups.METHODSThirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups.Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients.RESULTSEosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients.Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.CONCLUSIONEosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Thirty-two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine-aspirin nasal provocation test (L-ASA NPT) and 14 aspirin-tolerant asthma (ATA) patients who showed negative responses to the L-ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L-ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L-ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up-regulation of apolipoprotein A1 (ApoA1), α2-macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients. Eosinophil activation occurred in early and late responses after L-ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.
Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective To investigate the mechanism of eosinophil activation and identify novel inflammatory mediators using proteomics. Methods Thirty‐two asthmatic subjects were enrolled: 18 AERD patients who showed positive responses to the lysine‐aspirin nasal provocation test (L‐ASA NPT) and 14 aspirin‐tolerant asthma (ATA) patients who showed negative responses to the L‐ASA NPT (control group). Nasal lavage fluid (NLF) was collected before (baseline), at 10, 30 and 60 min (early response), and at 3 h (late response) after the L‐ASA NPT. Eosinophil cationic protein (ECP) and cysteinyl leucotriene (CysLT) levels were measured using an ImmunoCAP system and ELISA respectively. To identify proteins involved in AERD, comparative proteomics was applied using NLFs collected before and after L‐ASA NPTs in AERD patients. The clinical relevance of identified novel proteins was evaluated by ELISA using NLFs from the AERD and ATA groups. Results Eosinophil cationic protein and CysLT levels both increased significantly during the early response in AERD. ECP levels increased until the late response in AERD, while CysLT levels were not significantly increased during the late response. Proteomic analysis showed up‐regulation of apolipoprotein A1 (ApoA1), α2‐macroglobulin (α2M) and ceruloplasmin (CP), with significant increases in NLF of AERD patients, which was significantly higher in AERD patients with chronic rhinosinusitis. Significant correlations were noted between ECP and CysLT, ApoA1, α2M and CP levels during the early response in AERD patients. Conclusion Eosinophil activation occurred in early and late responses after L‐ASA NPT in upper airway mucosa of AERD patients, where ApoA1, α2M and CP as well as CysLT may be involved in eosinophilic inflammation.
Author Park, H.-S.
Shin, Y.-S.
Ye, Y.-M.
Choi, G.-S.
Kim, J.-H.
Kim, S.-H.
Author_xml – sequence: 1
  givenname: G.-S.
  surname: Choi
  fullname: Choi, G.-S.
  organization: Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea
– sequence: 2
  givenname: J.-H.
  surname: Kim
  fullname: Kim, J.-H.
  organization: Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea
– sequence: 3
  givenname: Y.-S.
  surname: Shin
  fullname: Shin, Y.-S.
  organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
– sequence: 4
  givenname: Y.-M.
  surname: Ye
  fullname: Ye, Y.-M.
  organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
– sequence: 5
  givenname: S.-H.
  surname: Kim
  fullname: Kim, S.-H.
  organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
– sequence: 6
  givenname: H.-S.
  surname: Park
  fullname: Park, H.-S.
  email: Hae-Sim Park, Department of Allergy and Clinical Immunology, Ajou University School of Medicine164 Worldcup-ro, Yeongtong-gu, Suwon 443-721, Korea., hspark@ajou.ac.kr
  organization: Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23786280$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1uEzEYRS1URNPCghdAI7GBxbT-Gf8toyQURFQkBHRpOZ5vVJeJPdgzhb49bpOwqEDi23hzzpV87wk6CjEAQi8JPiPlzh3YM0KxFk_QjDDBa1ruCM2w5k0tlW6O0UnONxhjxrV6ho4pk0pQhWfoahWzD3G49n1l3ehv7ehjqGxoqxBvoa-20Ho7xpQrH6rxGiqbB598qH1oJwcFs9n2VYI8xJDhnpqvPi-fo6ed7TO82L-n6Ou71ZfF-3r96eLDYr6uXaOxqKXTG6Wwa5hTim0UthIYda1TmNBNhxulOitJ41jLqZJcCAe6xY1lSjmAjp2iN7vcIcUfE-TRbH120Pc2QJyyIUxrTXEp5T9QiQUTosEFff0IvYlTCuUjhnCqOcWU60K92lPTptRkhuS3Nt2ZQ7sFON8BLsWcE3TG-fGh4DFZ3xuCzf1-puxnHvYrxttHxiH0b-w-_afv4e7foFms5gej3hk-j_Drj2HTdyMkk9xcXV6Yb4ItL8XHpVmz3-7ctkA
CitedBy_id crossref_primary_10_1080_02770903_2019_1652644
crossref_primary_10_1007_s11882_015_0569_2
crossref_primary_10_1021_pr500935s
crossref_primary_10_1111_all_13075
crossref_primary_10_1016_j_alit_2024_08_008
crossref_primary_10_1111_all_14620
crossref_primary_10_56782_pps_38
crossref_primary_10_2500_ajra_2015_29_4154
crossref_primary_10_1007_s00405_016_4273_1
crossref_primary_10_1016_j_bjorl_2015_01_003
crossref_primary_10_1186_s12970_015_0085_8
crossref_primary_10_3390_ijms23105703
crossref_primary_10_1016_j_lfs_2020_118973
crossref_primary_10_1016_j_rmed_2018_01_002
crossref_primary_10_1111_cea_12442
crossref_primary_10_1097_ACI_0000000000000122
crossref_primary_10_4168_aair_2016_8_6_481
crossref_primary_10_1097_ACI_0000000000000021
crossref_primary_10_1097_MCP_0000000000000010
crossref_primary_10_3389_fgene_2018_00363
crossref_primary_10_1002_prca_201300108
crossref_primary_10_1136_jramc_2015_000608
crossref_primary_10_1097_MCP_0000000000000328
crossref_primary_10_1016_j_anai_2015_02_009
crossref_primary_10_1186_s12931_018_0909_6
crossref_primary_10_1016_j_clim_2015_05_012
crossref_primary_10_1586_1744666X_2015_1039940
crossref_primary_10_3390_ijms22094377
crossref_primary_10_1016_j_jim_2021_113101
crossref_primary_10_1080_17476348_2018_1417843
crossref_primary_10_4168_aair_2022_14_5_479
crossref_primary_10_1080_02770903_2017_1341522
Cites_doi 10.1371/journal.pone.0022711
10.1042/bj2450781
10.1164/ajrccm.156.5.9702072
10.1385/CRIAI:24:2:113
10.1016/S0021-9258(18)80094-1
10.1136/thorax.55.11.921
10.1002/pmic.200300562
10.1161/ATVBAHA.112.300135
10.1159/000312669
10.1164/rccm.201010-1623OC
10.1111/j.1398-9995.2006.00993.x
10.1111/j.1365-2222.2008.03190.x
10.1155/2000/907478
10.3349/ymj.2009.50.6.744
10.1183/09031936.00138707
10.1016/B978-0-323-05659-5.00069-3
10.1164/rccm.200505-740OC
10.1080/01902140802220625
10.1016/j.jaci.2006.07.024
10.1111/j.1398-9995.2007.01409.x
10.1111/j.1365-2222.2009.03216.x
10.1111/j.1398-9995.2009.02158.x
10.1111/j.1365-2222.1995.tb01000.x
10.1159/000070474
10.4193/Rhino50E2
10.4168/aair.2012.4.2.68
10.1034/j.1398-9995.2003.00276.x
10.4168/aair.2011.3.1.3
10.1016/S0021-9258(18)80072-2
10.1164/ajrccm.149.4.8143059
10.1016/S0021-9258(19)57337-9
10.1016/S0952-3278(03)00074-7
10.1016/j.jaci.2009.12.977
10.1016/S1081-1206(10)60615-1
10.1007/s11882-006-0035-2
10.1067/mai.2003.1487
10.1111/j.1398-9995.2011.02557.x
10.1378/chest.128.5.3127
10.1016/j.atherosclerosis.2005.11.035
10.1067/mai.2003.25
10.1002/jlb.55.2.183
10.1046/j.1365-2222.2002.01384.x
10.1016/j.jaci.2005.08.035
10.1034/j.1398-9995.2002.t01-1-13447.x
10.1016/S1081-1206(10)62815-3
10.1194/jlr.M004549
10.1016/S1081-1206(10)62084-4
10.1016/j.jaci.2008.07.034
10.1111/j.1365-2222.1996.tb00612.x
10.1136/thx.2008.101196
10.1378/chest.11-0158
ContentType Journal Article
Copyright 2013 John Wiley & Sons Ltd
2013 John Wiley & Sons Ltd.
Copyright © 2013 John Wiley & Sons Ltd
Copyright_xml – notice: 2013 John Wiley & Sons Ltd
– notice: 2013 John Wiley & Sons Ltd.
– notice: Copyright © 2013 John Wiley & Sons Ltd
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
DOI 10.1111/cea.12096
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2222
EndPage 740
ExternalDocumentID 3317426841
23786280
10_1111_cea_12096
CEA12096
ark_67375_WNG_V63DN6KD_L
Genre article
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: KOSEF
– fundername: Korea government
  funderid: 2009‐0078646
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OB
1OC
29B
31~
33P
36B
3O-
3SF
4.4
4P2
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEGXH
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AHEFC
AHMBA
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOETA
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
EDH
EJD
EMB
EMK
EMOBN
ESTFP
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
YFH
YUY
ZGI
ZXP
ZZTAW
~IA
~WT
AAHHS
ACCFJ
ADZOD
AEEZP
AEQDE
AEUQT
AFPWT
AIWBW
AJBDE
WRC
WUP
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
K9.
7X8
ID FETCH-LOGICAL-c4906-7c9b880c43c883b80a7e32cdc8012bf0488fa714c3d5287566ce9d04a388ceef3
IEDL.DBID DR2
ISSN 0954-7894
1365-2222
IngestDate Sun Sep 28 06:16:31 EDT 2025
Fri Sep 05 08:46:28 EDT 2025
Sun Jul 13 04:00:23 EDT 2025
Mon Jul 21 06:05:09 EDT 2025
Tue Jul 01 02:53:22 EDT 2025
Thu Apr 24 23:01:28 EDT 2025
Wed Jan 22 16:36:49 EST 2025
Tue Sep 09 05:32:15 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2013 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4906-7c9b880c43c883b80a7e32cdc8012bf0488fa714c3d5287566ce9d04a388ceef3
Notes ark:/67375/WNG-V63DN6KD-L
ArticleID:CEA12096
istex:7E95D2EDF5B8F0ED3334DAB3590A3CD26F4B9EB9
KOSEF
Korea government - No. 2009-0078646
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
PMID 23786280
PQID 1529520259
PQPubID 36521
PageCount 11
ParticipantIDs proquest_miscellaneous_1399920365
proquest_miscellaneous_1370636640
proquest_journals_1529520259
pubmed_primary_23786280
crossref_citationtrail_10_1111_cea_12096
crossref_primary_10_1111_cea_12096
wiley_primary_10_1111_cea_12096_CEA12096
istex_primary_ark_67375_WNG_V63DN6KD_L
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2013
PublicationDateYYYYMMDD 2013-07-01
PublicationDate_xml – month: 07
  year: 2013
  text: July 2013
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Clinical and experimental allergy
PublicationTitleAlternate Clin Exp Allergy
PublicationYear 2013
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997; 156:1384-9.
Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010; 85:336-49.
Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076-82.
Yamashita T, Tsuji H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8:15-24.
Sladek K, Dworski R, Soja J et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940-6.
Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J 2009; 50:744-50.
Min JW, Jang AS, Park SM et al. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005; 128:3127-32.
Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8.
Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807-14.
Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187:238-50.
Wang W, Xu H, Shi Y et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-70.
Cho YM, Bae SH, Choi BK et al. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 2003; 3:1883-94.
Fuentes-Beltran A, Montes-Vizuet R, Valencia-Maqueda E, Negrete-García MC, García-Cruz Mde L, Teran LM. Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. Clin Exp Allergy 2009; 39:491-9.
Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91.
Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-8.
Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002; 32:745-50.
Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78.
Huang SS, O'Grady P, Huang JS. Human transforming growth factor beta-alpha 2-macroglobulin complex is a latent form of transforming growth factor beta. J Biol Chem 1988; 263:1535-41.
Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113-24.
Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-34.
Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012; 4:68-79.
Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006; 6:198-202.
Reddy VY, Pizzo SV, Weiss SJ. Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem 1989; 264:13801-9.
Lee SH, Rhim T, Choi YS et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370-8.
Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5.
Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55:183-91.
Park HS, Nahm DH, Park K, Suh KS, Yim HE. Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol 1998; 81:219-24.
Ben-Yehuda C, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Airway eosinophil accumulation and eotaxin-2/CCL24 expression following allergen challenge in BALB/c mice. Exp Lung Res 2008; 34:467-79.
Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69:135-43.
Hur GY, Choi GS, Sheen SS et al. Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2008; 122:774-80.
Vural H, Uzun K. Serum and red blood cell antioxidant status in patients with bronchial asthma. Can Respir J 2000; 7:476-80.
Kim TH, Lee JY, Park JS et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. PLoS ONE 2011; 6:e22711.
Fokkens WJ, Lund VJ, Mullol J et al. EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1-12.
Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma. Allergy 2002; 57:632-5.
Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21.
Hemelaers L, Henket M, Sele J, Bureau F, Louis R. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy 2006; 61:136-9.
Nagata M, Saito K. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003; 131:7-10.
Pods R, Ross D, van Hulst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58:1165-70.
Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012; 32:2561-5.
Yao X, Remaley AT, Levine SJ. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 2011; 140:1048-54.
Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-43.
Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264:11539-42.
Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2010; 65:338-46.
Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy 1995; 25:38-40.
Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3-10.
Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
Choi GS, Park HJ, Hur GY et al. Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 2009; 39:655-61.
Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987; 245:781-7.
Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66:818-29.
Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55:921-4.
Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-86.
2002; 57
1997; 156
2000; 7
2003; 58
2006; 173
2008; 34
1998; 81
1988; 263
2008; 31
2003; 111
2010; 65
1994; 149
2006; 61
2009; 50
1995; 25
2002; 89
2000; 55
1989; 264
2003; 3
2011; 66
2007; 62
2008; 63
1996; 26
1987; 245
2010; 125
2005; 116
2002; 32
1989; 8
2009
2006; 6
2011; 3
2008; 122
2007; 99
2006; 118
2011; 6
2010; 85
2012; 32
2003; 131
2012; 50
2005; 128
2003; 24
2003; 69
1994; 55
2006; 187
2011; 140
2012; 4
2011; 183
2010; 51
2009; 39
e_1_2_7_5_1
e_1_2_7_3_1
Huang SS (e_1_2_7_48_1) 1988; 263
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_17_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_37_1
e_1_2_7_39_1
Reddy VY (e_1_2_7_50_1) 1989; 264
e_1_2_7_6_1
e_1_2_7_4_1
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_10_1
e_1_2_7_46_1
Yamashita T (e_1_2_7_9_1) 1989; 8
e_1_2_7_27_1
e_1_2_7_29_1
e_1_2_7_51_1
e_1_2_7_30_1
e_1_2_7_53_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
References_xml – reference: Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89:474-8.
– reference: Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31:143-78.
– reference: Spada CS, Nieves AL, Krauss AH, Woodward DF. Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994; 55:183-91.
– reference: Ben-Yehuda C, Bader R, Puxeddu I, Levi-Schaffer F, Breuer R, Berkman N. Airway eosinophil accumulation and eotaxin-2/CCL24 expression following allergen challenge in BALB/c mice. Exp Lung Res 2008; 34:467-79.
– reference: Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-91.
– reference: Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264:11539-42.
– reference: Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24:113-24.
– reference: Reddy VY, Pizzo SV, Weiss SJ. Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem 1989; 264:13801-9.
– reference: Bandeira-Melo C, Weller PF. Eosinophils and cysteinyl leukotrienes. Prostaglandins Leukot Essent Fatty Acids 2003; 69:135-43.
– reference: Park HS, Nahm DH, Park K, Suh KS, Yim HE. Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin-sensitive asthmatic patients. Ann Allergy Asthma Immunol 1998; 81:219-24.
– reference: Lee SH, Rhim T, Choi YS et al. Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 2006; 173:370-8.
– reference: Fuentes-Beltran A, Montes-Vizuet R, Valencia-Maqueda E, Negrete-García MC, García-Cruz Mde L, Teran LM. Chemokine CC-ligand 5 production and eosinophil activation into the upper airways of aspirin-sensitive patients. Clin Exp Allergy 2009; 39:491-9.
– reference: Huang SS, O'Grady P, Huang JS. Human transforming growth factor beta-alpha 2-macroglobulin complex is a latent form of transforming growth factor beta. J Biol Chem 1988; 263:1535-41.
– reference: Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007; 62:1111-8.
– reference: Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987; 245:781-7.
– reference: Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63:1076-82.
– reference: Kim TH, Lee JY, Park JS et al. Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease. PLoS ONE 2011; 6:e22711.
– reference: Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55:921-4.
– reference: Yao X, Remaley AT, Levine SJ. New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma. Chest 2011; 140:1048-54.
– reference: Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma. Allergy 2002; 57:632-5.
– reference: Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res 2011; 3:3-10.
– reference: Sladek K, Dworski R, Soja J et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940-6.
– reference: Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, diagnosis, and treatment of aspirin intolerance. Ann Allergy Asthma Immunol 2007; 99:13-21.
– reference: Palikhe NS, Kim JH, Park HS. Update on recent advances in the management of aspirin exacerbated respiratory disease. Yonsei Med J 2009; 50:744-50.
– reference: Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002; 32:745-50.
– reference: Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006; 6:198-202.
– reference: Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
– reference: Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006; 118:773-86.
– reference: Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5.
– reference: Park HS. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy 1995; 25:38-40.
– reference: Kowalski ML, Grzegorczyk J, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA-sensitive patients. Clin Exp Allergy 1996; 26:807-14.
– reference: Vural H, Uzun K. Serum and red blood cell antioxidant status in patients with bronchial asthma. Can Respir J 2000; 7:476-80.
– reference: Kowalski ML, Makowska JS, Blanca M et al. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66:818-29.
– reference: Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187:238-50.
– reference: Cho YM, Bae SH, Choi BK et al. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 2003; 3:1883-94.
– reference: Palikhe NS, Kim SH, Cho BY, Ye YM, Choi GS, Park HS. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2010; 65:338-46.
– reference: Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-34.
– reference: Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997; 156:1384-9.
– reference: Choi GS, Park HJ, Hur GY et al. Vascular endothelial growth factor in allergen-induced nasal inflammation. Clin Exp Allergy 2009; 39:655-61.
– reference: Pods R, Ross D, van Hulst S, Rudack C, Maune S. RANTES, eotaxin and eotaxin-2 expression and production in patients with aspirin triad. Allergy 2003; 58:1165-70.
– reference: Hur GY, Choi GS, Sheen SS et al. Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma. J Allergy Clin Immunol 2008; 122:774-80.
– reference: Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010; 85:336-49.
– reference: Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012; 4:68-79.
– reference: Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-43.
– reference: Wang W, Xu H, Shi Y et al. Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res 2010; 51:2560-70.
– reference: Nagata M, Saito K. The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways. Int Arch Allergy Immunol 2003; 131:7-10.
– reference: Min JW, Jang AS, Park SM et al. Comparison of plasma eotaxin family level in aspirin-induced and aspirin-tolerant asthma patients. Chest 2005; 128:3127-32.
– reference: Fokkens WJ, Lund VJ, Mullol J et al. EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50:1-12.
– reference: Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol 2012; 32:2561-5.
– reference: Yamashita T, Tsuji H, Maeda N, Tomoda K, Kumazawa T. Etiology of nasal polyps associated with aspirin-sensitive asthma. Rhinol Suppl 1989; 8:15-24.
– reference: Hemelaers L, Henket M, Sele J, Bureau F, Louis R. Cysteinyl-leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics. Allergy 2006; 61:136-9.
– volume: 111
  start-page: S18
  year: 2003
  end-page: 34
  article-title: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling
  publication-title: J Allergy Clin Immunol
– volume: 245
  start-page: 781
  year: 1987
  end-page: 7
  article-title: Interaction and complex‐formation between the eosinophil cationic protein and alpha 2‐macroglobulin
  publication-title: Biochem J
– volume: 55
  start-page: 921
  year: 2000
  end-page: 4
  article-title: Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry
  publication-title: Thorax
– volume: 62
  start-page: 1111
  year: 2007
  end-page: 8
  article-title: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity
  publication-title: Allergy
– volume: 131
  start-page: 7
  year: 2003
  end-page: 10
  article-title: The roles of cysteinyl leukotrienes in eosinophilic inflammation of asthmatic airways
  publication-title: Int Arch Allergy Immunol
– volume: 156
  start-page: 1384
  year: 1997
  end-page: 9
  article-title: Expression of interleukin‐5 and granulocyte‐macrophage colony‐stimulating factor in aspirin‐sensitive and non‐aspirin‐sensitive asthmatic airways
  publication-title: Am J Respir Crit Care Med
– volume: 125
  start-page: 1084
  year: 2010
  end-page: 91
  article-title: Profile of eicosanoid generation in aspirin‐intolerant asthma and anaphylaxis assessed by new biomarkers
  publication-title: J Allergy Clin Immunol
– volume: 111
  start-page: 913
  year: 2003
  end-page: 21
  article-title: Aspirin‐induced asthma: advances in pathogenesis, diagnosis, and management
  publication-title: J Allergy Clin Immunol
– volume: 50
  start-page: 1
  year: 2012
  end-page: 12
  article-title: EPOS2012:European Position Paper on Rhinosinusitis and Nasal Polyps 2012
  publication-title: A summary for otorhinolaryngologists. Rhinology
– volume: 26
  start-page: 807
  year: 1996
  end-page: 14
  article-title: Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA‐sensitive patients
  publication-title: Clin Exp Allergy
– volume: 25
  start-page: 38
  year: 1995
  end-page: 40
  article-title: Early and late onset asthmatic responses following lysine‐aspirin inhalation in aspirin‐sensitive asthmatic patients
  publication-title: Clin Exp Allergy
– volume: 6
  start-page: e22711
  year: 2011
  article-title: Fatty acid binding protein 1 is related with development of aspirin‐exacerbated respiratory disease
  publication-title: PLoS ONE
– volume: 69
  start-page: 135
  year: 2003
  end-page: 43
  article-title: Eosinophils and cysteinyl leukotrienes
  publication-title: Prostaglandins Leukot Essent Fatty Acids
– volume: 263
  start-page: 1535
  year: 1988
  end-page: 41
  article-title: Human transforming growth factor beta–alpha 2‐macroglobulin complex is a latent form of transforming growth factor beta
  publication-title: J Biol Chem
– volume: 4
  start-page: 68
  year: 2012
  end-page: 79
  article-title: Eosinophil development, regulation of eosinophil‐specific genes, and role of eosinophils in the pathogenesis of asthma
  publication-title: Allergy Asthma Immunol Res
– volume: 61
  start-page: 136
  year: 2006
  end-page: 9
  article-title: Cysteinyl‐leukotrienes contribute to sputum eosinophil chemotactic activity in asthmatics
  publication-title: Allergy
– volume: 264
  start-page: 11539
  year: 1989
  end-page: 42
  article-title: Alpha‐macroglobulins: structure, shape, and mechanism of proteinase complex formation
  publication-title: J Biol Chem
– volume: 183
  start-page: 1633
  year: 2011
  end-page: 43
  article-title: Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease
  publication-title: Am J Respir Crit Care Med
– volume: 187
  start-page: 238
  year: 2006
  end-page: 50
  article-title: Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor?
  publication-title: Atherosclerosis
– volume: 50
  start-page: 744
  year: 2009
  end-page: 50
  article-title: Update on recent advances in the management of aspirin exacerbated respiratory disease
  publication-title: Yonsei Med J
– volume: 173
  start-page: 370
  year: 2006
  end-page: 8
  article-title: Complement C3a and C4a increased in plasma of patients with aspirin‐induced asthma
  publication-title: Am J Respir Crit Care Med
– volume: 39
  start-page: 655
  year: 2009
  end-page: 61
  article-title: Vascular endothelial growth factor in allergen‐induced nasal inflammation
  publication-title: Clin Exp Allergy
– volume: 7
  start-page: 476
  year: 2000
  end-page: 80
  article-title: Serum and red blood cell antioxidant status in patients with bronchial asthma
  publication-title: Can Respir J
– volume: 31
  start-page: 143
  year: 2008
  end-page: 78
  article-title: Global strategy for asthma management and prevention: GINA executive summary
  publication-title: Eur Respir J
– volume: 99
  start-page: 13
  year: 2007
  end-page: 21
  article-title: Pathogenesis, diagnosis, and treatment of aspirin intolerance
  publication-title: Ann Allergy Asthma Immunol
– volume: 89
  start-page: 474
  year: 2002
  end-page: 8
  article-title: The natural history and clinical characteristics of aspirin‐exacerbated respiratory disease
  publication-title: Ann Allergy Asthma Immunol
– volume: 85
  start-page: 336
  year: 2010
  end-page: 49
  article-title: Cysteinyl leukotrienes and their receptors: molecular and functional characteristics
  publication-title: Pharmacology
– volume: 24
  start-page: 113
  year: 2003
  end-page: 24
  article-title: Natural history and clinical features of aspirin‐exacerbated respiratory disease
  publication-title: Clin Rev Allergy Immunol
– volume: 34
  start-page: 467
  year: 2008
  end-page: 79
  article-title: Airway eosinophil accumulation and eotaxin‐2/CCL24 expression following allergen challenge in BALB/c mice
  publication-title: Exp Lung Res
– volume: 57
  start-page: 632
  year: 2002
  end-page: 5
  article-title: Nasal provocation test with aspirin: a sensitive and safe method to diagnose aspirin‐induced asthma
  publication-title: Allergy
– volume: 81
  start-page: 219
  year: 1998
  end-page: 24
  article-title: Immunohistochemical characterization of cellular infiltrate in nasal polyp from aspirin‐sensitive asthmatic patients
  publication-title: Ann Allergy Asthma Immunol
– volume: 3
  start-page: 3
  year: 2011
  end-page: 10
  article-title: Aspirin‐exacerbated respiratory disease: evaluation and management
  publication-title: Allergy Asthma Immunol Res
– volume: 116
  start-page: 970
  year: 2005
  end-page: 5
  article-title: Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult‐to‐treat asthma
  publication-title: J Allergy Clin Immunol
– volume: 55
  start-page: 183
  year: 1994
  end-page: 91
  article-title: Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility
  publication-title: J Leukoc Biol
– volume: 58
  start-page: 1165
  year: 2003
  end-page: 70
  article-title: RANTES, eotaxin and eotaxin‐2 expression and production in patients with aspirin triad
  publication-title: Allergy
– volume: 140
  start-page: 1048
  year: 2011
  end-page: 54
  article-title: New kids on the block: the emerging role of apolipoproteins in the pathogenesis and treatment of asthma
  publication-title: Chest
– start-page: 1227
  year: 2009
  end-page: 40
– volume: 8
  start-page: 15
  year: 1989
  end-page: 24
  article-title: Etiology of nasal polyps associated with aspirin‐sensitive asthma
  publication-title: Rhinol Suppl
– volume: 65
  start-page: 338
  year: 2010
  end-page: 46
  article-title: Genetic variability in CRTH2 polymorphism increases eotaxin‐2 levels in patients with aspirin exacerbated respiratory disease
  publication-title: Allergy
– volume: 6
  start-page: 198
  year: 2006
  end-page: 202
  article-title: Mechanisms of aspirin sensitivity
  publication-title: Curr Allergy Asthma Rep
– volume: 264
  start-page: 13801
  year: 1989
  end-page: 9
  article-title: Functional inactivation and structural disruption of human alpha 2‐macroglobulin by neutrophils and eosinophils
  publication-title: J Biol Chem
– volume: 118
  start-page: 773
  year: 2006
  end-page: 86
  article-title: Clinical and pathologic perspectives on aspirin sensitivity and asthma
  publication-title: J Allergy Clin Immunol
– volume: 32
  start-page: 745
  year: 2002
  end-page: 50
  article-title: Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor‐mediated mechanism
  publication-title: Clin Exp Allergy
– volume: 66
  start-page: 818
  year: 2011
  end-page: 29
  article-title: Hypersensitivity to non‐steroidal anti‐inflammatory drugs (NSAIDs) ‐ classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*
  publication-title: Allergy
– volume: 39
  start-page: 491
  year: 2009
  end-page: 9
  article-title: Chemokine CC‐ligand 5 production and eosinophil activation into the upper airways of aspirin‐sensitive patients
  publication-title: Clin Exp Allergy
– volume: 32
  start-page: 2561
  year: 2012
  end-page: 5
  article-title: High density lipoprotein biogenesis, cholesterol efflux, and immune cell function
  publication-title: Arterioscler Thromb Vasc Biol
– volume: 3
  start-page: 1883
  year: 2003
  end-page: 94
  article-title: Differential expression of the liver proteome in senescence accelerated mice
  publication-title: Proteomics
– volume: 128
  start-page: 3127
  year: 2005
  end-page: 32
  article-title: Comparison of plasma eotaxin family level in aspirin‐induced and aspirin‐tolerant asthma patients
  publication-title: Chest
– volume: 149
  start-page: 940
  year: 1994
  end-page: 6
  article-title: Eicosanoids in bronchoalveolar lavage fluid of aspirin‐intolerant patients with asthma after aspirin challenge
  publication-title: Am J Respir Crit Care Med
– volume: 122
  start-page: 774
  year: 2008
  end-page: 80
  article-title: Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate‐induced occupational asthma
  publication-title: J Allergy Clin Immunol
– volume: 51
  start-page: 2560
  year: 2010
  end-page: 70
  article-title: Genetic deletion of apolipoprotein A‐I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung
  publication-title: J Lipid Res
– volume: 63
  start-page: 1076
  year: 2008
  end-page: 82
  article-title: Increased levels of cysteinyl‐leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin‐intolerant asthma
  publication-title: Thorax
– ident: e_1_2_7_42_1
  doi: 10.1371/journal.pone.0022711
– ident: e_1_2_7_49_1
  doi: 10.1042/bj2450781
– ident: e_1_2_7_40_1
  doi: 10.1164/ajrccm.156.5.9702072
– ident: e_1_2_7_6_1
  doi: 10.1385/CRIAI:24:2:113
– ident: e_1_2_7_47_1
  doi: 10.1016/S0021-9258(18)80094-1
– ident: e_1_2_7_24_1
  doi: 10.1136/thorax.55.11.921
– ident: e_1_2_7_29_1
  doi: 10.1002/pmic.200300562
– ident: e_1_2_7_44_1
  doi: 10.1161/ATVBAHA.112.300135
– ident: e_1_2_7_13_1
  doi: 10.1159/000312669
– ident: e_1_2_7_52_1
  doi: 10.1164/rccm.201010-1623OC
– ident: e_1_2_7_14_1
  doi: 10.1111/j.1398-9995.2006.00993.x
– ident: e_1_2_7_41_1
  doi: 10.1111/j.1365-2222.2008.03190.x
– ident: e_1_2_7_53_1
  doi: 10.1155/2000/907478
– ident: e_1_2_7_33_1
  doi: 10.3349/ymj.2009.50.6.744
– ident: e_1_2_7_21_1
  doi: 10.1183/09031936.00138707
– volume: 8
  start-page: 15
  year: 1989
  ident: e_1_2_7_9_1
  article-title: Etiology of nasal polyps associated with aspirin‐sensitive asthma
  publication-title: Rhinol Suppl
– ident: e_1_2_7_2_1
  doi: 10.1016/B978-0-323-05659-5.00069-3
– ident: e_1_2_7_43_1
  doi: 10.1164/rccm.200505-740OC
– ident: e_1_2_7_19_1
  doi: 10.1080/01902140802220625
– ident: e_1_2_7_31_1
  doi: 10.1016/j.jaci.2006.07.024
– ident: e_1_2_7_25_1
  doi: 10.1111/j.1398-9995.2007.01409.x
– ident: e_1_2_7_27_1
  doi: 10.1111/j.1365-2222.2009.03216.x
– ident: e_1_2_7_17_1
  doi: 10.1111/j.1398-9995.2009.02158.x
– ident: e_1_2_7_22_1
  doi: 10.1111/j.1365-2222.1995.tb01000.x
– ident: e_1_2_7_37_1
  doi: 10.1159/000070474
– ident: e_1_2_7_23_1
  doi: 10.4193/Rhino50E2
– ident: e_1_2_7_20_1
  doi: 10.4168/aair.2012.4.2.68
– ident: e_1_2_7_39_1
  doi: 10.1034/j.1398-9995.2003.00276.x
– ident: e_1_2_7_3_1
  doi: 10.4168/aair.2011.3.1.3
– volume: 264
  start-page: 13801
  year: 1989
  ident: e_1_2_7_50_1
  article-title: Functional inactivation and structural disruption of human alpha 2‐macroglobulin by neutrophils and eosinophils
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)80072-2
– ident: e_1_2_7_10_1
  doi: 10.1164/ajrccm.149.4.8143059
– volume: 263
  start-page: 1535
  year: 1988
  ident: e_1_2_7_48_1
  article-title: Human transforming growth factor beta–alpha 2‐macroglobulin complex is a latent form of transforming growth factor beta
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(19)57337-9
– ident: e_1_2_7_11_1
  doi: 10.1016/S0952-3278(03)00074-7
– ident: e_1_2_7_12_1
  doi: 10.1016/j.jaci.2009.12.977
– ident: e_1_2_7_7_1
  doi: 10.1016/S1081-1206(10)60615-1
– ident: e_1_2_7_30_1
  doi: 10.1007/s11882-006-0035-2
– ident: e_1_2_7_32_1
  doi: 10.1067/mai.2003.1487
– ident: e_1_2_7_4_1
  doi: 10.1111/j.1398-9995.2011.02557.x
– ident: e_1_2_7_18_1
  doi: 10.1378/chest.128.5.3127
– ident: e_1_2_7_51_1
  doi: 10.1016/j.atherosclerosis.2005.11.035
– ident: e_1_2_7_36_1
  doi: 10.1067/mai.2003.25
– ident: e_1_2_7_15_1
  doi: 10.1002/jlb.55.2.183
– ident: e_1_2_7_16_1
  doi: 10.1046/j.1365-2222.2002.01384.x
– ident: e_1_2_7_8_1
  doi: 10.1016/j.jaci.2005.08.035
– ident: e_1_2_7_26_1
  doi: 10.1034/j.1398-9995.2002.t01-1-13447.x
– ident: e_1_2_7_35_1
  doi: 10.1016/S1081-1206(10)62815-3
– ident: e_1_2_7_45_1
  doi: 10.1194/jlr.M004549
– ident: e_1_2_7_5_1
  doi: 10.1016/S1081-1206(10)62084-4
– ident: e_1_2_7_28_1
  doi: 10.1016/j.jaci.2008.07.034
– ident: e_1_2_7_38_1
  doi: 10.1111/j.1365-2222.1996.tb00612.x
– ident: e_1_2_7_34_1
  doi: 10.1136/thx.2008.101196
– ident: e_1_2_7_46_1
  doi: 10.1378/chest.11-0158
SSID ssj0003598
Score 2.242018
Snippet Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin‐exacerbated respiratory disease (AERD). Objective...
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism...
Summary Background Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). Objective...
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD).BACKGROUNDEosinophil...
Eosinophil activation is the key feature of upper and lower airway inflammation in aspirin-exacerbated respiratory disease (AERD). To investigate the mechanism...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 730
SubjectTerms Adult
alpha-Macroglobulins - metabolism
Apolipoprotein A-I - metabolism
aspirin-exacerbated respiratory disease
Asthma, Aspirin-Induced - metabolism
Asthma, Aspirin-Induced - pathology
Biomarkers - metabolism
Ceruloplasmin - metabolism
CysLT
Cysteine - metabolism
eosinophil
Eosinophil Cationic Protein - metabolism
Eosinophils - metabolism
Eosinophils - pathology
Female
Humans
Inflammation - metabolism
Inflammation - pathology
Inflammation Mediators - metabolism
Leukotrienes - metabolism
Male
Middle Aged
Nasal Lavage Fluid
Nasal Provocation Tests
proteomics
Proteomics - methods
Respiratory Mucosa - metabolism
Respiratory Mucosa - pathology
Title Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD
URI https://api.istex.fr/ark:/67375/WNG-V63DN6KD-L/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcea.12096
https://www.ncbi.nlm.nih.gov/pubmed/23786280
https://www.proquest.com/docview/1529520259
https://www.proquest.com/docview/1370636640
https://www.proquest.com/docview/1399920365
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1365-2222
  dateEnd: 20240930
  omitProxy: true
  ssIdentifier: ssj0003598
  issn: 0954-7894
  databaseCode: ABDBF
  dateStart: 19890101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 0954-7894
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1365-2222
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0003598
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB1VRSBeuBQogYIMQqgvWWVjO3HE06q7pQK6DxWFIiFFtuOIVVdJtRcEPPEJfCNfwoxzgaKCEG-Rcqwk9kx87BmfAXhS8sykhraXXCRCoY0MVcmLUCupdOpUnPk6ZIfT5OBYvDiRJxvwrDsL0-hD9Btu5Bn-f00Ors3yFye3Tg_o4CfJbQ-59CHao5_SUaRM1-jsiTBVmWhVhSiLp295bi66RN366SKieZ63-oln_zq87165yTc5HaxXZmC__Kbm-J_fdAOutYSUjRoLugkbrtqCy02Jys9bcOWwDb7fgneTejmr6rMPszmj4xDNZi7TVcGq-qObM38Khar3sFnFkFgyTWH8WfX96zdc-aMNIVAv8WGLJjHXEW40ORrfhuP9yeu9g7CtzBBakUVJmNrMoONbwa1S3KgIh5XHtrA035mS_gqlTofC8kLikgwpo3VZEQnNlcJZueR3YLOqK3cXWFmWXDuZWqWdECbKTCwQWUgTO2UKHcBuN0a5bWXLqXrGPO-WL9hpue-0AB730LNGq-Mi0FM_0D1CL04puS2V-dvp8_xNwsfT5OU4fxXATmcJeevXy3xIcdEYeWIWwKP-NnokhVl05eo1YniKvC9JRPQ3DBJzigHLALYbK-tfKOYpLjMVtt71tvLnb8n3JiN_ce_foffhauwrelDG8Q5srhZr9wB51co89A70AzlXHL8
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVjwuPMorUCAghHrJKo2dxJG4rLpbFrq7h6qF9oAs23HEqquk2gcCTvwEfiO_hBknGygqCHGLlM-KY8_Yn2fGMwDPC5bpVJN5yYY84ErHgShYHigRC5VaEWWuDtlonAyO-Jvj-HgNXq7uwtT5IVqDG2mGW69Jwckg_YuWG6s6dPMzuQQb5J8jtewd_EweRbnp6kx7PEhFxpu8QhTH0zY9txtt0MB-uohqnmeubuvZuwHvV52uI05OO8uF7pgvv-Vz_N-_ugnXG07qd2shugVrttyEy3WVys-bcGXU-N9vw0m_mk_K6uzDZOrTjYjanuurMvfL6qOd-u4iChXw8Selj9zSV-TJn5Tfv37Dwz-KEQLVHD82q2NzLeG6_YPeHTja6x_uDoKmOENgeBYmQWoyjbpvODNCMC1CnFkWmdzQlqcLWhgKle5ww_IYT2XIGo3N8pArJgRuzAW7C-tlVdr74BdFwZSNUyOU5VyHmY44IvNYR1boXHmwvZokaZrM5VRAYypXJxgcNOkGzYNnLfSsTtdxEeiFm-kWoWanFN-WxvLd-JV8m7DeONnvyaEHWytRkI1qz-UOuUYjpIqZB0_b16iU5GlRpa2WiGEpUr8k4eHfMMjNyQ0ce3CvFrO2QxFL8aQpsPW2E5Y__4vc7Xfdw4N_hz6Bq4PD0VAOX4_3H8K1yBX4oADkLVhfzJb2EdKshX7stOkH9BUg2w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB2VVlS8cCmXBgoEhFBfskpjJ3HE06q7S6HtClUUWgnJsh1HXXWVrPaCgCc-gW_kS5hxsoGighBvkXKsOPaMfcYzngF4VrBMp5qOl2zIA650HIiC5YESsVCpFVHm6pAdDpO9Y_76JD5ZgRfLuzB1foj2wI00w63XpOCTvPhFyY1VHbr4mVyBNZ6gdUWM6Ohn7ihKTVcn2uNBKjLepBWiMJ626YXNaI3G9dNlTPMicXU7z-AGfFj2uQ44Oe8s5rpjvvyWzvE_f-omXG8Yqd-tRegWrNhyA67WNSo_b8D6YeN9vw2n_Wo2KqvJ2Wjs032I-jTXV2Xul9VHO_bdNRQq3-OPSh-Zpa_Ijz8qv3_9hqY_ChEC1Qw_Nq0jcy3huv2j3h04HvTf7u4FTWmGwPAsTILUZBo133BmhGBahDivLDK5oQ1PF7QsFCrd4YblMdpkyBmNzfKQKyYEbssFuwurZVXaTfCLomDKxqkRynKuw0xHHJF5rCMrdK482F7OkTRN3nIqnzGWS_sFB026QfPgaQud1Mk6LgM9dxPdItT0nKLb0li-H76U7xLWGyb7PXngwdZSEmSj2DO5Q47RCIli5sGT9jWqJPlZVGmrBWJYisQvSXj4Nwwyc3ICxx7cq6Ws7VDEUrQzBbbedrLy53-Ru_2ue7j_79DHsP6mN5AHr4b7D-Ba5Kp7UPTxFqzOpwv7EDnWXD9yuvQDeG8fig
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Eosinophil+activation+and+novel+mediators+in+the+aspirin-induced+nasal+response+in+AERD&rft.jtitle=Clinical+and+experimental+allergy&rft.au=Choi%2C+G-S&rft.au=Kim%2C+J-H&rft.au=Shin%2C+Y-S&rft.au=Ye%2C+Y-M&rft.date=2013-07-01&rft.issn=0954-7894&rft.eissn=1365-2222&rft.volume=43&rft.issue=7&rft.spage=730&rft.epage=740&rft_id=info:doi/10.1111%2Fcea.12096&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-7894&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-7894&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-7894&client=summon